摘要
目的评价甲泼尼松龙与布地奈德治疗慢性阻塞性肺疾病急性加重期(AECOPD)合并2型糖尿病患者的临床效果。方法将100例AECOPD合并2型糖尿病患者随机分为A组(50例)和B组(50例)。A组给予布地奈德雾化吸入治疗,B组给予甲泼尼松龙静脉滴注治疗。对比两组患者治疗前后的血糖指标(空腹血糖、餐后2 h血糖、糖化血红蛋白)、血气指标(动脉二氧化碳分压、动脉血氧分压)及临床疗效。结果治疗前,两组的血气指标及血糖指标比较无统计学差异(P>0.05)。治疗后,B组的空腹血糖、餐后2 h血糖、糖化血红蛋白水平高于治疗前及A组(P <0.05);两组的血气指标均优于治疗前(P <0.05),但两组的血气指标与治疗总有效率比较无统计学差异(P>0.05)。结论布地奈德雾化吸入与甲泼尼松龙静脉滴注治疗AECOPD合并2型糖尿病患者均具有满意的临床效果,可有效改善血气指标,但布地奈德雾化吸入对血糖指标的副作用更少。
Objective To evaluate the clinical effect of methylprednisolone and budesonide in the treatment of patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD) complicated with type 2 diabetes. Methods 100 patients with AECOPD complicated with type 2 diabetes were randomly divided into group A(50 cases) and group B(50 cases). Group A was given budesonide atomization inhalation, and group B was given methylprednisolone intravenous infusion. The blood glucose indicators(fasting blood glucose, 2 h postprandial blood glucose, glycated hemoglobin), blood gas indicators(arterial carbon dioxide partial pressure, arterial blood oxygen partial pressure) before and after treatment and clinical efficacy were compared between the two groups. Results Before treatment,no statistical difference was found in the blood gas indicators and blood glucose indicators between the two groups(P >0.05). After treatment, the fasting blood glucose, 2 h postprandial blood glucose and glycated hemoglobin levels of group B were higher than those before treatment and those of group A(P <0.05);The blood gas indicators of two groups were better than those before treatment(P <0.05). No statistical difference was found in the blood gas indicators and the total effective rate of treatment between the two groups(P >0.05).Conclusions Budesonide atomization inhalation and methylprednisolone intravenous infusion in the treatment of patients with AECOPD complicated with type 2 diabetes have satisfactory clinical effect, and can effectively improve the blood gas indicators. But budesonide atomization inhalation has fewer side effects on blood glucose indicators.
作者
周星求
ZHOU Xingqiu(Xiaolan People's Hospital,Zhongshan 528415,China)
出处
《临床医学工程》
2020年第5期593-594,共2页
Clinical Medicine & Engineering
关键词
甲泼尼松龙
布地奈德
慢性阻塞性肺疾病急性加重期
2型糖尿病
Methylprednisolone
Budesonide
Acute exacerbation of chronic obstructive pulmonary disease
Type 2 diabetes
